These individuals will receive standard of care for post operative recovery following a prostatectomy.

These individuals will receive post operative physical therapy in addition to standard of care for post operative recovery following a prostatectomy.

Prostate Cancer

Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.

Physical Therapy

Jennifer Stone

Pelvic Health and Physical Therapy to Improve Lives of Prostate Cancer Patients Undergoing Prostatectomy

Pelvic Health and Physical Therapy to Improve Lives of Prostate Cancer Patients

Change in IPPS from preoperative through to 18 months post operatively, assessed at intervals

Change in IIEF from preoperative through to 18 months post operatively, assessed at intervals

Change in NIH-CPSI from preoperative through to 18 months post operatively, assessed at intervals

Change in Pain VAS from preoperative through to 18 months post operatively, assessed at intervals

Change in BDI from preoperative through to 18 months post operatively, assessed at intervals

Change in Bristol Stool Scale from preoperative through to 18 months post operatively, assessed at intervals

Change in strength from preoperative through to 18 months post operatively, assessed at intervals

Jennifer Y Stone

Manager, Clinical Rehabilitative Services

University of Missouri-Columbia

Randomization into treatment and standard of care groups. Treatment group will receive physical therapy in addition to standard of care treatment.

Patients receive Bacillus Calmette-Guérin induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG).

Patients received BCG treatment with the same protocol. Intervention will be a 40 mg mitomycin instillation the day before every single BCG instillation

Bladder Cancer

Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .

Mitomycin

Sequential Combination Therapy in Bladder Cancer

The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer

To evaluate the effect in term of recurrence rate of sequential combination therapy of Mitomycin and Bacillus Calmette-Guérin versus Bacillus Calmette-Guérin monotherapy in patients with High grade Non-Muscle Invasive Bladder Cancer.through cystoscopy every three months and Uro Tomography Computerized yearly

To evaluate the overall toxicity of sequential combination therapy of Mitomycin and Bacillus Calmette-Guérin versus Bacillus Calmette-Guérin monotherapy through CTCAE v4.0. Patients have to fill in International Prostate Symptoms Score, NIH-CPSI, PUF questionaries. Every three months patients will be visited and have a cystoscopy. We will hear about self-reported symptoms and we will measure body temperature

Azienda Ospedaliera "Sant'Andrea"

The subjects will be assessed for eligibility at the screening visit (Visit 1) three weeks after TURB and re-TURB prior to randomization and only subjects who fulfil the inclusion criteria will be included: patients with a diagnosis of High risk NMIBC: T1 tumor, G3, CIS, or multiple and recurrent and large (>3 cm) Ta or patients in the last EAU recurrence category (EAU/EORTC recurrence score >/=10). Patients selected for the study, are centrally randomized (randomization is performed at the Sant'Andrea Hospital) to receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG). Patients in group two received BCG treatment with the same protocol with a 40 mg mitomycin instillation the day before .

Brentuximab Vedotin dose will start at 1.2 mg/kg by intravenous (IV) infusion on Day1 and Day15 plus Cyclophosphamide 500mg/m2 IV on Day1 plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5 plus Etoposide 60mg/m2 OR on Day15 through 19 plus Mitoxantrone 6mg/m2 IV on Day15 and Prednisone 30mg/m2 on Day1 through 5 of each 28-day treatment cycles for up to 6 total treatment cycles (approximately 24 weeks or 6 months)

Hodgkin Lymphoma

All patients will be treated with 6 cycles of BV-EPEM

BrentuximabVedotin (BV)

Institut Català d'Oncologia, Hospital Germans Trias i Pujol

Institut Català d'Oncologia, Hospital Duran i Reynals

Hospital Costa del Sol

Hospital Clinic i Provincial de Barcelona

Hospital Vall d'Hebron

Hospital de Basurto

Hospital General Universitario Gregorio Marañon

Hospital Universitario 12 de Octubre

Hospital Universitario La Paz

Hospital Son Llatzer

Hospital Universitario de Salamanca

Hospital Universitario Donostia - Arantzazu

Hospital Universitario Marqués de Valdecilla

Hospital Universitario Virgen del Rocío

Hospital Universitario Miguel Servet

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)

To identify the maximum tolerated dose (MTD) of Brentuximab Vedotin (BV) in combination with EPEM

To assess the percentage of patients with complete response rate after BV-EPEM treatment.

To evaluate the toxicity of the treatment by measure of number of treatment-related adverse events according to CTCAE v4.0

Evaluation of patient without progression of disease

length of time between date of evidence response and progression of disease or death

To evaluate overall response rate (ORR) based on best response (CR and PR) and the tumor local control rate (CR, PR, and stable disease [SD]) with this treatment regimen.

To assess the type, frequency, severity and relationship of adverse events (AEs) to this treatment regimen.

evaluation of patients alive after first dose of treatment and follow up

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Takeda

Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone

Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).

Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone
BCG (Immucist®)

BCG Alone (Immucist®)

Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).
Hyaluronic Acid
BCG (Immucist®)

Hyaluronic Acid

Total

Sex: Female, Male

Race (NIH/OMB)

Region of Enrollment

1 to 10 scale (1 minimum pain perceivable; 10 unbearable pain, as perceived by the patient)

prostatitis/koorts

Pelvic Health and Physical Therapy to Improve Lives of Prostate Cancer Patients Undergoing Prostatectomy

Sequential Combination Therapy in Bladder Cancer

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects

Laparoscopic Prostatectomy for Chronic Prostatitis

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap